HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | RFA NS 22 034

Opportunity Information: Apply for RFA NS 22 034

The HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) funding opportunity (RFA-NS-22-034) is an NIH research grant designed to push early-stage, basic science work that identifies and thoroughly validates new therapeutic targets for pain. The central idea is to strengthen the upstream part of the pain-therapeutics pipeline by finding biological targets that can later be used to create safer and more effective treatments, especially treatments that avoid the major drawbacks of many current pain medications, such as significant side effects and abuse or addiction liability. Rather than funding later-stage product development, the FOA prioritizes foundational discovery and the kind of rigorous target validation that makes a target credible and “ready” for downstream translational programs.

Scientifically, the FOA is broad about where promising targets might come from and encourages investigators to look across multiple systems and tissues. Responsive research can focus on the peripheral nervous system, central nervous system, immune system, and other relevant tissues in the body that influence pain signaling, modulation, and persistence. The emphasis is on identifying novel targets and then backing those targets up with strong validation data that demonstrates robustness and reproducibility. In practical terms, applicants are expected to go beyond a single intriguing finding and instead build a compelling evidence package showing that the target meaningfully affects pain-related biology and is likely to be useful for therapeutic intervention.

A key requirement is that projects include rigorous validation studies. The purpose of this requirement is risk reduction: by demonstrating that a target holds up under careful testing, the research lowers the chance that later translational teams invest heavily in a target that turns out to be unreliable, context-dependent, or not truly connected to pain mechanisms. The FOA frames this validation as a bridge between discovery and future translation, where later programs might develop small molecules, biologics, natural substances, or devices that interact with the validated target. Even so, the work supported here is not meant to be clinical testing, and the announcement is explicit that clinical trials are not allowed under this R01.

The opportunity is intentionally not limited to one pain condition. NIH will consider projects proposing targets relevant to acute pain and a wide range of chronic pain states and disorders, including migraine and other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, and post-stroke pain, among others. It also welcomes approaches that address chronic overlapping pain conditions or targets tied to particular pathological contexts, which reflects an interest in mechanisms that may cut across diagnoses or explain why certain pain conditions persist and resist current therapies. In addition, the FOA signals responsiveness to projects that focus on specific populations, such as women, children, older adults, and other underrepresented groups, supporting discovery that could help address disparities or population-specific pain biology.

From a scope standpoint, the FOA draws a line between discovery/validation and device development. While future translation could involve devices, this particular announcement states that translational research to develop new medical devices is not the focus. Applicants should therefore stay anchored in basic discovery and target validation rather than proposing engineering-driven device development programs.

On the administrative side, this is a discretionary NIH grant using the R01 mechanism, and it falls under multiple CFDA numbers (93.121, 93.213, 93.273, 93.350, 93.393, 93.846, 93.847, 93.853, 93.865, 93.866), reflecting participation across NIH institutes and centers. The original closing date listed is 2024-12-06. The award ceiling and expected number of awards are not specified in the provided listing.

Eligibility is broad and includes many common applicant types: state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other entities. The FOA also explicitly calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). Overall, the announcement is set up to attract a wide research community while keeping the scientific emphasis tightly centered on discovering and validating novel pain-relevant targets that could lead to safer, non-addictive pain treatments.

• The National Institutes of Health in the education, food and nutrition, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.350, 93.393, 93.846, 93.847, 93.853, 93.865, 93.866.
• This funding opportunity was created on 2022-01-07.
• Applicants must submit their applications by 2024-12-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 22 034

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: